Hormonal
Endothelial dysfunction, characterized by impaired nitric oxide (NO) production and increased asymmetric dimethylarginine (ADMA), is an early and independent predictor of cardiovascular events in diabetes, often preceding clinical symptoms.
Your blood vessels' ability to dilate and function properly (endothelial function) is a critical early indicator of heart disease risk, often before plaque builds up. In diabetes, this function is impaired due to low nitric oxide and high ADMA. Managing insulin sensitivity and reducing oxidative stress can help improve endothelial health and reduce CVD risk.
Endothelial dysfunction is now recognized as being an early abnormality in the natural history of CVD and may be a good predictor of cardiovascular events... NO-mediated vasodilation is impaired in non-insulin-dependent diabetes mellitus... Impaired endothelial function was first associated with CVD... epicardial and microvascular coronary endothelial dysfunction independently predict acute cardiovascular events...
Why this rating
Cited studies include prospective follow-ups showing endothelial dysfunction predicts events independently of angiographic findings.
Source
Nontraditional Risk Factors for Cardiovascular Disease in Diabetes
Vivian Fonseca et al. · Endocrine Reviews · 2004
DOI 10.1210/er.2002-0034
More from this paper
- Insulin resistance (IR) and hyperinsulinemia are independent, nontraditional risk factors for cardiovascular disease (CVD) in type 2 diabetes, contributing to excess morbidity and mortality beyond traditional risk factors like hypertension and dyslipidemia.Good
- Inflammation, marked by elevated C-reactive protein (CRP), white blood cells, and adhesion molecules, is a key nontraditional risk factor for CVD in diabetes, linked to insulin resistance and obesity.Good
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →